BioSpace News Archive

Appoints Tim Largen as VP of Manufacturing to drive cell therapy production strategy and direct collaborations with leading CDMOs

Funds will support the company’s mission of advancing noninvasive treatment options for people with reduced tissue perfusion

RedHill Biopharma Ltd. today announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in hospitalized patients with severe COVID-19 pneumonia.

Twist Bioscience Corporation today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 AY.1 and AY.2

Neurogene Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for NGN-101. NGN-101

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference

Rafael Holdings, Inc., a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced the appointment of Patrick Fabbio as Chief Financial Officer.

Anixa Biosciences, Inc. (NASDAQ: ANIX), announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance’s Emerging Immunotherapeutics for Ovarian Cancer Symposium

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that the company has strengthened its leadership team with the appointment of Gudarz Davar, M.D., as executive vice president, chief medical officer and the promotion of Chan Beals, M.D., Ph.D., to senior vice president, chief of translational medicine.

OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Healthcare division, Spacelabs Healthcare®, received an order valued at approximately $3 million to provide patient monitoring solutions and related accessories to a Midwestern U.S. based hospital.